Clinical Trials Logo

Filter by:
NCT ID: NCT03541772 Completed - Head Cancer Neck Clinical Trials

Evaluation of Oncoxin-Viusid® in Head and Neck Cancer

Start date: January 20, 2015
Phase: Phase 2
Study type: Interventional

Nutritional supplements containing antioxidants seem to decrease toxicity associated with Radiotherapy (RT) and Chemotherapy (CT) in patients with malignant head and neck tumors. Oncoxin-Viusid® (OV) is a nutritional supplement with antioxidant, immunomodulator and antitumor effects.

NCT ID: NCT03541148 Completed - Clinical trials for Cutaneous Melanoma, Stage III

Evaluation of Oncoxin-Viusid® in Cutaneous Melanoma

Start date: September 16, 2014
Phase: Phase 2
Study type: Interventional

Malignant melanoma, responsible for 75% of deaths from skin cancer. Current therapeutic options have poor response, many adverse events and high costs. For this reason, a study with nutritional supplement Oncoxin-Viusid was carried out. According to previous studies, it has an antitumor, immunomodulatory effect and to potentiate the antiproliferative effect of standard chemotherapeutic agents in different locations and stages of cancer.

NCT ID: NCT03541005 Completed - Clinical trials for Overweight and Obesity

Evaluation of Obex® in Overweight and Obesity

Start date: October 1, 2018
Phase: Phase 3
Study type: Interventional

- Obesity is an important and growing worldwide - Obesity is highly related to the development of metabolic syndrome, diabetes, cardiovascular diseases and cancer - Diverse adverse events have been reported with the use of antiobesity drugs. - Several articles describe the beneficial effect of several specific components of the Obex® supplement on weight loss, in the reduction of waist circumference, suppression of appetite, decrease fasting glucose levels, improvement of insulin sensitivity and β cells function. - Therefore, the administration of Obex in overweight and obese patients could be an excellent strategy to induce weight loss and ameliorate the metabolic disturbances related to obesity and overweight.

NCT ID: NCT03540407 Completed - Clinical trials for Cervical Carcinoma Stage III

Evaluation of Oncoxin-Viusid® in Cervical Cancer and Endometrial Adenocarcinoma.

Start date: January 7, 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy of oral solution Oncoxin-Viusid in the reduction of acute toxicity of Radiotherapy (RTP) and Chemotherapy (QTP) in patients with histological diagnosis of cervical cancer and endometrial adenocarcinoma. This is a phase II, prospective, randomized and double blind clinical trial, which will include 66 patients assigned to 2 treatment arms: 33 patients will receive conventional treatment, plus a placebo of the nutritional supplement and another 33 patients will receive along with the conventional treatment the Oncoxin-Viusid nutritional supplement produced by the Catalysis Laboratories of Spain. Patients will receive oral treatment throughout the onco-specific treatment and up to 3 weeks after completion.

NCT ID: NCT03533478 Completed - Clinical trials for Diabetic Macular Edema

Alzer® and Diamel® to Prevent Severe Diabetes Macular Edema

Start date: March 1, 2015
Phase: Phase 2
Study type: Interventional

Macular edema is the main cause of low vision in diabetics. They continue looking for new treatment alternatives. The nutritional supplement Alzer, is a powerful antioxidant that together with Diamel, a supplement that has shown efficacy in metabolic control, could be a therapeutic option. Objective: To evaluate the therapeutic efficacy of the Alzer Diamel combination in mild and moderate macular edema. Material and method: A randomized double-blind phase II clinical trial versus placebo will be conducted in 64 patients, who will be randomly assigned to two groups, one will receive Alzer + Diamel and another will receive placebo from Alzer and Diamel. All patients will undergo clinical, biochemical and ophthalmological evaluation during the study.

NCT ID: NCT03393286 Completed - Zika Virus Clinical Trials

ZIKAlliance Children Cohort (ZIKAllianceCH)

ZIKAllianceCH
Start date: January 15, 2018
Phase:
Study type: Observational

The aim of this proposal is to evaluate the causal relationship between Zika virus (ZIKV) infections in pregnancy and congenital malformations. The study will estimate the absolute and relative risks of congenital malformations and other adverse outcomes of pregnancy among women who become infected with ZIKV during pregnancy compared to uninfected pregnant women, also leading to further validation of the Congenital Zika Syndrome.

NCT ID: NCT03296254 Completed - Clinical trials for Mental Health Wellness 1

Comparison of Two Brief Mindfulness Intervention for Stress, Anxiety and Burnout in Mental Health Professionals

Start date: January 22, 2018
Phase: N/A
Study type: Interventional

The aim of this study is to examine the effectiveness of two mindfulness interventions for stress, anxiety and burnout in mental health professionals. Participants will receive the treatments in reverse order: a brief intervention based on body-centered exercises and another brief intervention based on sitting meditation. It is hypothesized that both interventions will decrease stress and anxiety levels and professional burnout, with mindfulness body-centered exercises being at least as effective as mindfulness meditations.

NCT ID: NCT03188731 Completed - Pregnancy Related Clinical Trials

ZIKAlliance Pregnant Women Cohort

ZIKAlliancePW
Start date: May 24, 2017
Phase:
Study type: Observational

The aim of this proposal is to evaluate the causal relationship between Zika virus (ZIKV) infections in pregnancy and congenital malformations. We will estimate the absolute and relative risks of congenital malformations and other adverse outcomes of pregnancy among women who become infected with ZIKV during pregnancy compared to uninfected pregnant women, also leading to further validation of the Congenital Zika Syndrome.

NCT ID: NCT02862990 Completed - Breast Cancer Clinical Trials

Evaluation of the Attitude of Pre Menopausal Women With Breast Cancer Faced With the Risk of Fertility Loss Caused by Chemotherapy

Start date: May 2015
Phase:
Study type: Observational

To evaluate the attitude of pre menopausal women with breast cancer faced with the risk of loss of fertility caused by chemotherapy using EORTC's Fertility Questionnaire.

NCT ID: NCT02271958 Completed - Endometriosis Clinical Trials

Mifepristone 2.5, 5, 10 mg Versus Placebo in the Treatment of Endometriosis

Start date: November 2010
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to evaluate the effectiveness and safety of 2.5, 5 and 10 mg doses of mifepristone against a placebo in women with laparoscopic diagnostic of endometriosis. The hypothesis of the study is that the 5 mg mifepristone dose is safe and effective and should be used in future studies on medical treatment of endometriosis.